Digital health technologies and Alzheimer’s disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?

BACKGROUND: Therapeutic trials in Alzheimer’s disease (AD) face many obstacles—particularly with regard to screening and recruitment. DISCUSSION: Decentralized clinical trials (DCTs) are being developed in other diseases and appear to be of value for overcoming these difficulties. The use of remote...

Descripción completa

Detalles Bibliográficos
Autores principales: Leroy, Victoire, Gana, Wassim, Aïdoud, Amal, N’kodo, Jacques-Alexis, Balageas, Anna-Chloé, Blanc, Pascal, Bomia, Dominique, Debacq, Camille, Fougère, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133908/
https://www.ncbi.nlm.nih.gov/pubmed/37106429
http://dx.doi.org/10.1186/s13195-023-01227-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133908/
https://www.ncbi.nlm.nih.gov/pubmed/37106429
http://dx.doi.org/10.1186/s13195-023-01227-4

Ejemplares similares